Ikarian Capital, LLC Immuno Gen, Inc. Transaction History

Ikarian Capital, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $3.74 Million - $8.99 Million	-300,000 Reduced 76.89%	90,162 $2.67 Million
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $810,710 - $1.14 Million	-57,538 Reduced 12.85%	390,162 $6.19 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $1.68 Million - $8.98 Million	447,700 New	447,700 $8.45 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.